A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Immune globulin (Primary)
- Indications Autoimmune disorders; Neurological disorders; Obsessive-compulsive disorders; Psychiatric disorders
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 01 Aug 2024 Planned primary completion date changed from 6 Aug 2024 to 1 Oct 2024.
- 09 Jul 2024 Planned primary completion date changed from 1 Oct 2024 to 6 Aug 2024.
- 05 Jul 2024 Planned End Date changed from 29 Jun 2024 to 22 Oct 2024.